Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China
[TEXT NOT REPRODUCIBLE IN ASCII] [TEXT NOT REPRODUCIBLE IN ASCII] Metodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habian inscrito en el programa Integral y se recogieron datos administrativos relevantes de hospitales y la agenda de salud pu...
Gespeichert in:
| Veröffentlicht in: | Bulletin of the World Health Organization 2015-11, Vol.93 (11), p.775-775 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 775 |
|---|---|
| container_issue | 11 |
| container_start_page | 775 |
| container_title | Bulletin of the World Health Organization |
| container_volume | 93 |
| creator | Fitzpatrick, Christopher Hui, Zhang Lixia, Wang Renzhong, Li Yunzhou, Ruan Mingting, Chen Yanlin, Zhao Jin, Zhao Wei, Su Caihong, Xu Cheng, Chen Alston, Timothy Yan, Qu Chengfei, Lv Yunting, Fu Shitong, Huan Qiang, Sun Scano, Fabio Chin, Daniel P Floyd, Katherine |
| description | [TEXT NOT REPRODUCIBLE IN ASCII] [TEXT NOT REPRODUCIBLE IN ASCII] Metodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habian inscrito en el programa Integral y se recogieron datos administrativos relevantes de hospitales y la agenda de salud publica de China. Como termino de comparacion, se examino un cohorte de 81 pacientes que habian sido tratados para la tuberculosis farmacorresistente en 2006-2009. Se llevo a cabo un analisis de costoeficacia desde una perspectiva societaria que incluia la incertidumbre probabilistlca. Se midieron los resultados de los tratamientos tempranos basados en los resultados de un cultivo de tres meses y se modelaron resultados a largo plazo para facilitar la estimacion del coste del programa integral de anos de vida en funcion de la discapacidad (AVAD) evitada. |
| doi_str_mv | 10.2471/BLT.14.146274 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762377971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A436797326</galeid><sourcerecordid>A436797326</sourcerecordid><originalsourceid>FETCH-LOGICAL-g2371-e8dd2adc8a845e2291952a0a1f589d6fe8a52537d4dc61d541e1622ea126dda23</originalsourceid><addsrcrecordid>eNqNkk2P0zAQhgMCibJw5MTFEhILh7Sx4zjJcan4qKgEWpZzNGtP0qDEDraD9uczpStopR6II8WZPH7ekZ0kecGzpZAlX73b3iy5pFuJUj5MFrxQMs1UJh8liyyTIq1VpZ4kT0P4kdFVy2zx4OXahZhi26KO_S-0GAJzLQOm3Th53KENVGaTd52HcUTWOs-Mn7vUY-hDBBtZnG_R63lwVGC9Zetdb2F1DdPkfCTR_Ceg16D7iMxczvbI1w3uFgZmkA1zpM_a2ejpBY60lL8DP4J2f0OR4SEIV9t9syE6PETA3vUvAqijiDQb2AQeTsXUb3svPpjxyAzPksctDAGf3z8vku8f3t-sP6XbLx8366tt2om85ClWxggwuoJKFihEzetCQAa8LaraqBYrKESRl0YarbgpJEeuhEDgQhkDIr9I3hy81PLPGUNsxj5oHAaw6ObQ8FJRUFmXnNBXB7SDAZveti560Hu8uZK5IiYXiqj0DNXR6dI2OEsbReUTfnmGp2Fw7PXZBW9PFuwPDe9iB3MIzeevm_9mN9-uT9nXR-wOYYi74OjH6J0Nx-BveH7ybQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762377971</pqid></control><display><type>article</type><title>Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Fitzpatrick, Christopher ; Hui, Zhang ; Lixia, Wang ; Renzhong, Li ; Yunzhou, Ruan ; Mingting, Chen ; Yanlin, Zhao ; Jin, Zhao ; Wei, Su ; Caihong, Xu ; Cheng, Chen ; Alston, Timothy ; Yan, Qu ; Chengfei, Lv ; Yunting, Fu ; Shitong, Huan ; Qiang, Sun ; Scano, Fabio ; Chin, Daniel P ; Floyd, Katherine</creator><creatorcontrib>Fitzpatrick, Christopher ; Hui, Zhang ; Lixia, Wang ; Renzhong, Li ; Yunzhou, Ruan ; Mingting, Chen ; Yanlin, Zhao ; Jin, Zhao ; Wei, Su ; Caihong, Xu ; Cheng, Chen ; Alston, Timothy ; Yan, Qu ; Chengfei, Lv ; Yunting, Fu ; Shitong, Huan ; Qiang, Sun ; Scano, Fabio ; Chin, Daniel P ; Floyd, Katherine</creatorcontrib><description>[TEXT NOT REPRODUCIBLE IN ASCII] [TEXT NOT REPRODUCIBLE IN ASCII] Metodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habian inscrito en el programa Integral y se recogieron datos administrativos relevantes de hospitales y la agenda de salud publica de China. Como termino de comparacion, se examino un cohorte de 81 pacientes que habian sido tratados para la tuberculosis farmacorresistente en 2006-2009. Se llevo a cabo un analisis de costoeficacia desde una perspectiva societaria que incluia la incertidumbre probabilistlca. Se midieron los resultados de los tratamientos tempranos basados en los resultados de un cultivo de tres meses y se modelaron resultados a largo plazo para facilitar la estimacion del coste del programa integral de anos de vida en funcion de la discapacidad (AVAD) evitada.</description><identifier>ISSN: 0042-9686</identifier><identifier>EISSN: 1564-0604</identifier><identifier>DOI: 10.2471/BLT.14.146274</identifier><language>eng</language><publisher>World Health Organization</publisher><subject>Antitubercular agents ; Drug resistance in microorganisms ; Economic aspects ; Mycobacterium ; Tuberculosis</subject><ispartof>Bulletin of the World Health Organization, 2015-11, Vol.93 (11), p.775-775</ispartof><rights>COPYRIGHT 2015 World Health Organization</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27922,27923</link.rule.ids></links><search><creatorcontrib>Fitzpatrick, Christopher</creatorcontrib><creatorcontrib>Hui, Zhang</creatorcontrib><creatorcontrib>Lixia, Wang</creatorcontrib><creatorcontrib>Renzhong, Li</creatorcontrib><creatorcontrib>Yunzhou, Ruan</creatorcontrib><creatorcontrib>Mingting, Chen</creatorcontrib><creatorcontrib>Yanlin, Zhao</creatorcontrib><creatorcontrib>Jin, Zhao</creatorcontrib><creatorcontrib>Wei, Su</creatorcontrib><creatorcontrib>Caihong, Xu</creatorcontrib><creatorcontrib>Cheng, Chen</creatorcontrib><creatorcontrib>Alston, Timothy</creatorcontrib><creatorcontrib>Yan, Qu</creatorcontrib><creatorcontrib>Chengfei, Lv</creatorcontrib><creatorcontrib>Yunting, Fu</creatorcontrib><creatorcontrib>Shitong, Huan</creatorcontrib><creatorcontrib>Qiang, Sun</creatorcontrib><creatorcontrib>Scano, Fabio</creatorcontrib><creatorcontrib>Chin, Daniel P</creatorcontrib><creatorcontrib>Floyd, Katherine</creatorcontrib><title>Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China</title><title>Bulletin of the World Health Organization</title><description>[TEXT NOT REPRODUCIBLE IN ASCII] [TEXT NOT REPRODUCIBLE IN ASCII] Metodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habian inscrito en el programa Integral y se recogieron datos administrativos relevantes de hospitales y la agenda de salud publica de China. Como termino de comparacion, se examino un cohorte de 81 pacientes que habian sido tratados para la tuberculosis farmacorresistente en 2006-2009. Se llevo a cabo un analisis de costoeficacia desde una perspectiva societaria que incluia la incertidumbre probabilistlca. Se midieron los resultados de los tratamientos tempranos basados en los resultados de un cultivo de tres meses y se modelaron resultados a largo plazo para facilitar la estimacion del coste del programa integral de anos de vida en funcion de la discapacidad (AVAD) evitada.</description><subject>Antitubercular agents</subject><subject>Drug resistance in microorganisms</subject><subject>Economic aspects</subject><subject>Mycobacterium</subject><subject>Tuberculosis</subject><issn>0042-9686</issn><issn>1564-0604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>KPI</sourceid><recordid>eNqNkk2P0zAQhgMCibJw5MTFEhILh7Sx4zjJcan4qKgEWpZzNGtP0qDEDraD9uczpStopR6II8WZPH7ekZ0kecGzpZAlX73b3iy5pFuJUj5MFrxQMs1UJh8liyyTIq1VpZ4kT0P4kdFVy2zx4OXahZhi26KO_S-0GAJzLQOm3Th53KENVGaTd52HcUTWOs-Mn7vUY-hDBBtZnG_R63lwVGC9Zetdb2F1DdPkfCTR_Ceg16D7iMxczvbI1w3uFgZmkA1zpM_a2ejpBY60lL8DP4J2f0OR4SEIV9t9syE6PETA3vUvAqijiDQb2AQeTsXUb3svPpjxyAzPksctDAGf3z8vku8f3t-sP6XbLx8366tt2om85ClWxggwuoJKFihEzetCQAa8LaraqBYrKESRl0YarbgpJEeuhEDgQhkDIr9I3hy81PLPGUNsxj5oHAaw6ObQ8FJRUFmXnNBXB7SDAZveti560Hu8uZK5IiYXiqj0DNXR6dI2OEsbReUTfnmGp2Fw7PXZBW9PFuwPDe9iB3MIzeevm_9mN9-uT9nXR-wOYYi74OjH6J0Nx-BveH7ybQ</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Fitzpatrick, Christopher</creator><creator>Hui, Zhang</creator><creator>Lixia, Wang</creator><creator>Renzhong, Li</creator><creator>Yunzhou, Ruan</creator><creator>Mingting, Chen</creator><creator>Yanlin, Zhao</creator><creator>Jin, Zhao</creator><creator>Wei, Su</creator><creator>Caihong, Xu</creator><creator>Cheng, Chen</creator><creator>Alston, Timothy</creator><creator>Yan, Qu</creator><creator>Chengfei, Lv</creator><creator>Yunting, Fu</creator><creator>Shitong, Huan</creator><creator>Qiang, Sun</creator><creator>Scano, Fabio</creator><creator>Chin, Daniel P</creator><creator>Floyd, Katherine</creator><general>World Health Organization</general><scope>ISR</scope><scope>KPI</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20151101</creationdate><title>Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China</title><author>Fitzpatrick, Christopher ; Hui, Zhang ; Lixia, Wang ; Renzhong, Li ; Yunzhou, Ruan ; Mingting, Chen ; Yanlin, Zhao ; Jin, Zhao ; Wei, Su ; Caihong, Xu ; Cheng, Chen ; Alston, Timothy ; Yan, Qu ; Chengfei, Lv ; Yunting, Fu ; Shitong, Huan ; Qiang, Sun ; Scano, Fabio ; Chin, Daniel P ; Floyd, Katherine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g2371-e8dd2adc8a845e2291952a0a1f589d6fe8a52537d4dc61d541e1622ea126dda23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antitubercular agents</topic><topic>Drug resistance in microorganisms</topic><topic>Economic aspects</topic><topic>Mycobacterium</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fitzpatrick, Christopher</creatorcontrib><creatorcontrib>Hui, Zhang</creatorcontrib><creatorcontrib>Lixia, Wang</creatorcontrib><creatorcontrib>Renzhong, Li</creatorcontrib><creatorcontrib>Yunzhou, Ruan</creatorcontrib><creatorcontrib>Mingting, Chen</creatorcontrib><creatorcontrib>Yanlin, Zhao</creatorcontrib><creatorcontrib>Jin, Zhao</creatorcontrib><creatorcontrib>Wei, Su</creatorcontrib><creatorcontrib>Caihong, Xu</creatorcontrib><creatorcontrib>Cheng, Chen</creatorcontrib><creatorcontrib>Alston, Timothy</creatorcontrib><creatorcontrib>Yan, Qu</creatorcontrib><creatorcontrib>Chengfei, Lv</creatorcontrib><creatorcontrib>Yunting, Fu</creatorcontrib><creatorcontrib>Shitong, Huan</creatorcontrib><creatorcontrib>Qiang, Sun</creatorcontrib><creatorcontrib>Scano, Fabio</creatorcontrib><creatorcontrib>Chin, Daniel P</creatorcontrib><creatorcontrib>Floyd, Katherine</creatorcontrib><collection>Gale In Context: Science</collection><collection>Gale In Context: Global Issues</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Bulletin of the World Health Organization</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fitzpatrick, Christopher</au><au>Hui, Zhang</au><au>Lixia, Wang</au><au>Renzhong, Li</au><au>Yunzhou, Ruan</au><au>Mingting, Chen</au><au>Yanlin, Zhao</au><au>Jin, Zhao</au><au>Wei, Su</au><au>Caihong, Xu</au><au>Cheng, Chen</au><au>Alston, Timothy</au><au>Yan, Qu</au><au>Chengfei, Lv</au><au>Yunting, Fu</au><au>Shitong, Huan</au><au>Qiang, Sun</au><au>Scano, Fabio</au><au>Chin, Daniel P</au><au>Floyd, Katherine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China</atitle><jtitle>Bulletin of the World Health Organization</jtitle><date>2015-11-01</date><risdate>2015</risdate><volume>93</volume><issue>11</issue><spage>775</spage><epage>775</epage><pages>775-775</pages><issn>0042-9686</issn><eissn>1564-0604</eissn><abstract>[TEXT NOT REPRODUCIBLE IN ASCII] [TEXT NOT REPRODUCIBLE IN ASCII] Metodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habian inscrito en el programa Integral y se recogieron datos administrativos relevantes de hospitales y la agenda de salud publica de China. Como termino de comparacion, se examino un cohorte de 81 pacientes que habian sido tratados para la tuberculosis farmacorresistente en 2006-2009. Se llevo a cabo un analisis de costoeficacia desde una perspectiva societaria que incluia la incertidumbre probabilistlca. Se midieron los resultados de los tratamientos tempranos basados en los resultados de un cultivo de tres meses y se modelaron resultados a largo plazo para facilitar la estimacion del coste del programa integral de anos de vida en funcion de la discapacidad (AVAD) evitada.</abstract><pub>World Health Organization</pub><doi>10.2471/BLT.14.146274</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9686 |
| ispartof | Bulletin of the World Health Organization, 2015-11, Vol.93 (11), p.775-775 |
| issn | 0042-9686 1564-0604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1762377971 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antitubercular agents Drug resistance in microorganisms Economic aspects Mycobacterium Tuberculosis |
| title | Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China/Rapport cout-efficacite d'un programme global de lutte contre la tuberculose pharmacoresistante en Chine/La costoeficacia de un programa integral para la tuberculosis farmacorresistente en China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T15%3A23%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20a%20comprehensive%20programme%20for%20drug-resistant%20tuberculosis%20in%20China/Rapport%20cout-efficacite%20d'un%20programme%20global%20de%20lutte%20contre%20la%20tuberculose%20pharmacoresistante%20en%20Chine/La%20costoeficacia%20de%20un%20programa%20integral%20para%20la%20tuberculosis%20farmacorresistente%20en%20China&rft.jtitle=Bulletin%20of%20the%20World%20Health%20Organization&rft.au=Fitzpatrick,%20Christopher&rft.date=2015-11-01&rft.volume=93&rft.issue=11&rft.spage=775&rft.epage=775&rft.pages=775-775&rft.issn=0042-9686&rft.eissn=1564-0604&rft_id=info:doi/10.2471/BLT.14.146274&rft_dat=%3Cgale_proqu%3EA436797326%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762377971&rft_id=info:pmid/&rft_galeid=A436797326&rfr_iscdi=true |